Nivolumab is an immunotherapy drug approved for the treatment of several types of cancer, including melanoma, non-small cell lung cancer, and renal cell carcinoma, among others [1]. According to the drug's prescribing information, nivolumab is administered intravenously [2].

The U.S. Food and Drug Administration (FDA) has approved nivolumab for intravenous use in the form of a single-dose vial containing 10 mg/mL of the drug [3]. Nivolumab is typically administered over a period of 30 minutes, and the dosage is determined based on the patient's body weight and kidney function [2].

It is important to note that nivolumab should only be administered by healthcare professionals who have received proper training in the handling and administration of the drug [2]. Patients receiving nivolumab should be monitored for potential side effects, which can include immune-related adverse reactions such as skin rash, diarrhea, and endocrine disorders [2].

In summary, nivolumab is a cancer immunotherapy drug that is given intravenously. It is important for healthcare professionals to follow proper handling and administration guidelines to ensure patient safety and efficacy.

Sources:

1. DrugPatentWatch.com. Nivolumab. <https://www.drugpatentwatch.com/drugs/nivolumab>.
2. Bristol Myers Squibb. Opdivo (nivolumab) Prescribing Information. <https://packageinserts.bms.com/pi/pi_opdivo.pdf>.
3. U.S. Food and Drug Administration. FDA approves Opdivo (nivolumab) for previously treated advanced renal cell carcinoma. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-opdivo-nivolumab-previously-treated-advanced-renal-cell-carcinoma>.